NCT05524090Recruiting
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
Nationwide Implementation Program for Optimal Multidisciplinary Management and Resection of Locally Advanced Pancreatic Cancer (PREOPANC-4)
Source: ClinicalTrials.gov · Last updated 1 Sept 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021\[7\]-2030\[6\]), including a multidisciplinary training program by the four leading international expert centers. The PREOPANC-4 project aims a safe and patient-centered implementation of the international standards of excellence for LAPC (surgery) in the Netherlands.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 223 (estimated)
- First submitted
- 16 Aug 2022
- Start date
- 1 Jul 2021
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Diseases
- Pancreatic cancer
- NCT number
- NCT05524090
What you commit to
- Study type: Observational
- Planned participants: 223
- From 1 Jul 2021 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Metastatic pancreatic cancer prior to induction chemotherapy.
- According to the Dutch Pancreatic Cancer Group (DPCG) definition: \>90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and/or hepatic artery) and/or portovenous involvement of either \>270 degrees or occlusion.
Who the study is looking for
- Age 18 years or older
- Pathology-confirmed (LAPC)\*
- CT-based non-progressive disease (RECIST criteria) after at least 4 months of systemic chemotherapy (\[m\]FOLFIRINOX / gemcitabine-nab-paclitaxel).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC, locatie AMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
Related publications
- Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study.Br J Surg · 2026 · PMID 42329186
- Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international multicentre retrospective study.BJS Open · 2026 · PMID 42263216
This page is information, not medical advice. Discuss any trial with your doctor.